Detalles de la búsqueda
1.
Clinical characteristics and prognostic impact of immune checkpoint inhibitor-associated myocarditis in advanced non-small cell lung cancer.
Invest New Drugs;
41(6): 816-824, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37902905
2.
Chemoradiotherapy for untreated Masaoka-Koga stage IVB thymic carcinoma: a single-center retrospective study.
Strahlenther Onkol;
199(3): 313-321, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36729136
3.
Development and validation of prognostic nomogram for T1-3N0M0 non-small cell lung cancer after curative resection.
BMC Cancer;
23(1): 715, 2023 Jul 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-37525124
4.
Baseline C-reactive protein predicts efficacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma: a retrospective, multicenter study.
BMC Cancer;
23(1): 1244, 2023 Dec 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38104105
5.
Bcl6 drives stem-like memory macrophages differentiation to foster tumor progression.
Cell Mol Life Sci;
80(1): 14, 2022 Dec 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-36542153
6.
Predicting the efficacy of immune checkpoint inhibitors monotherapy in advanced non-small cell lung cancer: a machine learning method based on multidimensional data.
Neoplasma;
70(2): 300-310, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36812231
7.
Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations.
BMC Pulm Med;
23(1): 158, 2023 May 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37147602
8.
Treatment outcomes and prognosis of patients with primary and acquired BRAF-mutated non-small cell lung cancer: A multicenter retrospective study.
Genes Chromosomes Cancer;
61(9): 530-541, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35396765
9.
Targeting KRAS mutant cancers: from druggable therapy to drug resistance.
Mol Cancer;
21(1): 159, 2022 08 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35922812
10.
The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study.
Cancer Immunol Immunother;
71(7): 1693-1703, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-34817639
11.
Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial.
BMC Med;
20(1): 154, 2022 05 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35534877
12.
Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial.
BMC Med;
20(1): 42, 2022 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35101045
13.
Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective study.
BMC Cancer;
22(1): 576, 2022 May 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-35606756
14.
Clinical outcomes of EGFR-TKIs in advanced squamous cell lung cancer.
Neoplasma;
69(4): 976-982, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35603955
15.
The prognostic impact of immune checkpoint inhibitors for the treatment of pulmonary sarcomatoid carcinoma: A multicenter retrospective study.
Neoplasma;
69(6): 1437-1444, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36353935
16.
Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study.
BMC Pulm Med;
22(1): 179, 2022 May 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35524294
17.
Baseline anemia predicts a poor prognosis in patients with non-small cell lung cancer with epidermal growth factor receptor mutations: a retrospective study.
BMC Pulm Med;
22(1): 381, 2022 Oct 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-36253772
18.
EXT1 methylation promotes proliferation and migration and predicts the clinical outcome of non-small cell lung carcinoma via WNT signalling pathway.
J Cell Mol Med;
25(5): 2609-2620, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33565239
19.
Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study.
BMC Med;
19(1): 206, 2021 09 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-34511132
20.
The deep learning model combining CT image and clinicopathological information for predicting ALK fusion status and response to ALK-TKI therapy in non-small cell lung cancer patients.
Eur J Nucl Med Mol Imaging;
48(2): 361-371, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32794105